NCT02358681 - Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

Migraine

Interventions

DRUG

Ketorolac, intranasal

Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.

DRUG

Ketorolac, intravenous

Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.

DRUG

Placebo, intravenous

Placebo of equal volume to IV ketorolac, to be administered by intravenous route.

DRUG

Placebo, intranasal

Placebo of equal volume to IN ketorolac, to be administered by intranasal route.

Trial Locations (1)

NewYork Presbyterian Morgan Stanley Children's Hospital, New York